Burghardt Wittig
#80,393
Most Influential Person Now
German molecular biologist
Burghardt Wittig's AcademicInfluence.com Rankings
Burghardt Wittigbiology Degrees
Biology
#3976
World Rank
#6004
Historical Rank
Molecular Biology
#852
World Rank
#875
Historical Rank
Genetics
#1614
World Rank
#1720
Historical Rank
Download Badge
Biology
Why Is Burghardt Wittig Influential?
(Suggest an Edit or Addition)According to Wikipedia, Burghardt Wittig is the chairman of MolBio and a professor of biochemistry and molecular biology at Freie Universitaet Berlin in Berlin , Germany. His research focuses on the areas of gene regulation, DNA structures induced by torsional strain, chromatin structure, G-protein-mediated signal transduction, as well as therapeutic applications of genetic research and DNA-based vaccines. His research has been published in numerous leading scientific journals, including Cell, Nature, PNAS, and Science.
Burghardt Wittig's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents (1991) (569)
- Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. (1993) (376)
- Different β-subunits determine G-protein interaction with transmembrane receptors (1992) (360)
- Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. (2000) (335)
- Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma (1999) (221)
- Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. (1987) (211)
- Antisense Research and Application (1998) (204)
- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study (1998) (174)
- Transcription of human c‐myc in permeabilized nuclei is associated with formation of Z‐DNA in three discrete regions of the gene. (1992) (158)
- Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia (2003) (131)
- Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias (1998) (130)
- Transcription is associated with Z-DNA formation in metabolically active permeabilized mammalian cell nuclei. (1991) (115)
- Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. (1996) (112)
- Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. (1998) (110)
- Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection (2017) (99)
- Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. (1998) (95)
- A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. (2001) (94)
- TLR2‐activated human langerhans cells promote Th17 polarization via IL‐1β, TGF‐β and IL‐23 (2009) (94)
- Heat shock gene expression is regulated during teratocarcinoma cell differentiation and early embryonic development. (1983) (91)
- Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. (2001) (87)
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial (2014) (79)
- Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif (2000) (77)
- Subunit composition of G(o) proteins functionally coupling galanin receptors to voltage‐gated calcium channels. (1995) (77)
- Gi2 and protein kinase C are required for thyrotropin-releasing hormone-induced stimulation of voltage-dependent Ca2+ channels in rat pituitary GH3 cells. (1993) (76)
- A heterotrimeric G protein complex couples the muscarinic m1 receptor to phospholipase C-beta. (1996) (72)
- Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. (2003) (71)
- DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. (2002) (68)
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. (2015) (67)
- The level of Z-DNA in metabolically active, permeabilized mammalian cell nuclei is regulated by torsional strain (1989) (65)
- Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen–Derived HLA-A2–Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer (2005) (62)
- Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene (1998) (61)
- Human Langerhans cells selectively activated via Toll‐like receptor 2 agonists acquire migratory and CD4+T cell stimulatory capacity (2008) (54)
- Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide (2001) (53)
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study (2018) (53)
- Chromatin from transcribed genes contains HMG17 only downstream from the starting point of transcription. (1987) (53)
- Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. (2015) (52)
- Identification of transcriptionally induced Z-DNA segments in the human c-myc gene. (1995) (50)
- Gβγ Activation Site in Adenylyl Cyclase Type II (2006) (50)
- Logitlinear models for the prediction of splice sites in plant pre-mRNA sequences. (1996) (49)
- Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation (2000) (48)
- Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. (2019) (47)
- Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. (2000) (46)
- Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression (2000) (46)
- Function of a tRNA gene promoter depends on nucleosome position (1982) (42)
- A phase relationship associates tRNA structural gene sequences with nucleosome cores (1979) (42)
- Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703 (2015) (41)
- Schistosoma mansoni miracidia transformed by particle bombardment infect Biomphalaria glabrata snails and develop into transgenic sporocysts. (2003) (40)
- Isolation of oligonucleosomes from active chromatin using HMG17-specific monoclonal antibodies. (1986) (40)
- Specificity of interaction between receptor and G protein: use of antisense techniques to relate G-protein subunits to function. (1996) (39)
- Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region (2005) (39)
- DNA immunisation with minimalistic expression constructs. (2004) (37)
- Minimal size MIDGE vectors improve transgene expression in vivo. (2007) (37)
- Cytokine and Ig‐production by CG‐containing sequences with phosphorodiester backbone and dumbbell‐shape (2006) (34)
- The innate antiviral immune system of the cat: Molecular tools for the measurement of its state of activation (2011) (34)
- Genitourinary tumors, non-prostate (2012) (31)
- Peripheral non-viral MIDGE vector-driven delivery of β-endorphin in inflammatory pain (2009) (30)
- Cloning of an interferon regulatory factor 2 isoform with different regulatory ability. (2000) (28)
- The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon (2017) (28)
- Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. (1994) (27)
- Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. (1997) (26)
- Gbetagamma activation site in adenylyl cyclase type II. Adenylyl cyclase type III is inhibited by Gbetagamma. (2006) (26)
- Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. (2006) (26)
- Quantification of human cells in NOD/SCID mice by duplex real-time polymerase-chain reaction. (2001) (25)
- Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. (2008) (25)
- Lack of correlation between DNA methylation and transcriptional inactivation: the chicken lysozyme gene. (1991) (25)
- The loss of desmosomes after retinoic acid treatment results in an apparent inhibition of HaCaT keratinocyte differentiation (1999) (24)
- Influence of ballistic gene transfer on antigen-presenting cells in murine corneas (2002) (23)
- Genuine Immunomodulation With dSLIM (2014) (23)
- Two interaction sites on mammalian adenylyl cyclase type I and II: modulation by calmodulin and G(betagamma). (2008) (23)
- Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice (2003) (22)
- Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. (2010) (21)
- Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs (2001) (21)
- P53 and induction of apoptosis as a target for anticancer therapy. (1996) (20)
- Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. (2003) (20)
- Nucleosome mono, di, tri-, and tetramers from chicken embryo chromatin. (1977) (19)
- Retinoic acid receptor γ1 expression determines retinoid sensitivity in pancreatic carcinoma cells (1998) (19)
- Polymorphism at codon 554 of the human Ah receptor: different allelic frequencies in Caucasians and Japanese and no correlation with severity of TCDD induced chloracne in chemical workers. (1999) (19)
- Reverse transcription of tRNA. (1978) (19)
- Construction of a 42 base pair double stranded DNA microcircle. (1989) (19)
- Identification of processes that influence negative supercoiling in the human c-myc gene. (1997) (18)
- TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes (2019) (18)
- Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells (2000) (18)
- Z-DNA-forming sites within the human beta-globin gene cluster. (1996) (18)
- Minimizing side effects of ballistic gene transfer into the murine corneal epithelium (2002) (17)
- Microinjection of antisense oligonucleotides to assess G-protein subunit function. (1994) (17)
- Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors (2019) (17)
- No evidence for ‘stress’ α-globin genes in chicken (1982) (17)
- Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment (1998) (16)
- The promoter of the HaCaT keratinocyte differentiation-related gene keratin 4 contains a functional AP-2 binding site (1997) (15)
- Proliferation-dependent induction of apoptosis by the retinoid CD437 in p53-mutated keratinocytes (2001) (15)
- Preclinical study on combined chemo‐ and nonviral gene therapy for sensitization of melanoma using a human TNF‐alpha expressing MIDGE DNA vector (2014) (15)
- Regulation and possible function of axl expression in immature human mast cells (1998) (15)
- Effect of netropsin, distamycin A and chromomycin A3 on the binding and cleavage reaction of DNA gyrase (1994) (14)
- Keratinocytes rapidly readjust ceramide-sphingomyelin homeostasis and contain a phosphatidylcholine-sphingomyelin transacylase. (2004) (14)
- TLR 2-activated human langerhans cells promote Th 17 polarization via IL-1 b , TGF-b and IL-23 (2009) (13)
- Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release. (2015) (13)
- Purification of the four lysine-specific transfer ribonucleic acids from chick embryos. (1973) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Comparison of non-viral transfection methods in melanoma cell primary cultures. (2000) (10)
- Transcription termination and processing of transcripts from tRNA-related Xenopus satellite DNA sequences. (1987) (10)
- Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context (2016) (10)
- TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer. (1999) (9)
- EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy (2019) (8)
- Prevention and synergistic control of Ph(+) ALL by a DNA vaccine and 6-mercaptopurine. (2012) (7)
- Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival. (2015) (7)
- Interleukin 7 trials for melanoma treatment. (1996) (7)
- Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study. (2014) (6)
- Novel procedure of elution and concentration of nucleic acids with NACS Prepac minicolumns by electrophoresis. (1985) (6)
- Brief Communication: Stability and Catalytic Activity of Novel Circular DNAzymes (2006) (6)
- MIDGE Vectors and dSLIM Immunomodulators: DNA‐based Molecules for Gene Therapeutic Strategies (2008) (6)
- Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma (1995) (6)
- Purification of class A, B, and C DNA-dependent RNA polymerases from chicken embryos. (1978) (5)
- Microinjection of antisense oligonucleotides and electrophysiological recording of whole-cell currents as tools to identify specific G-protein subtypes coupling hormone receptors to voltage-gated calcium channels. (1998) (5)
- Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report. (1998) (4)
- Synthesis of highly radioactively labelled RNA hybridization probes from synthetic single stranded DNA oligonucleotides. (1987) (4)
- 426. dSLIM Immunomodulators Induce Anti- Tumor Responses Both In Vitro and In Vivo (2006) (4)
- Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy. (2017) (4)
- Stabilization of R loop structures by photochemical crosslinking with 4,5',8-trimethylpsoralen: application to gene enrichment and molecular cloning. (1979) (4)
- Intratumoral dispersion, retention, systemic biodistribution, and clearance of a small-size tumor necrosis factor-α-expressing MIDGE vector after nonviral in vivo jet-injection gene transfer. (2012) (4)
- Retinoic acid receptor gamma1 expression determines retinoid sensitivity in pancreatic carcinoma cells. (1998) (4)
- dSLIM Immunomodulators Induce Anti-Tumor Responses Both In Vitro and In Vivo. (2005) (3)
- IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma. (2012) (3)
- Effects of 24 Week Toll -Like Receptor 9 Agonist Treatment in HIV-1+ Individuals: a single-arm, phase 1B/2A trial (2019) (3)
- Potent Phosphorodiester-Based DNA Immunomodulators (dSLIM) Exhibit Enhanced Safety Compared to Phosphorothioate-Based Oligonucleotides. (2005) (3)
- Specificity of the Receptor-G-Protein Interaction: Assigning Functions TO G-Protein Subunits by the Antisense Technique (1997) (3)
- Increase in proliferation rate and normalization of TNF-α secretion by blockage of gene transfer–induced apoptosis in lymphocytes using low-dose cyclosporine A (2000) (3)
- Studies on phenylalanine-specific transfer ribonucleic acid from chick embryos. (1974) (3)
- ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601. (2014) (3)
- Cloning of chicken embryo tRNA genes using single stranded nucleosomal DNA highly enriched for tRNA complementary sequences. (1979) (3)
- A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703. (2015) (3)
- Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C. (1997) (3)
- Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent (2015) (2)
- Modulation of T cell and macrophage tumor infiltration by the TLR9 agonist lefitolimod in a murine model of colorectal cancer. (2018) (2)
- Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study). (2011) (2)
- 1063PASET STUDY: FINAL RESULTS OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC RENAL CELL CARCINOMA (RCC) TREATED WITH MGN1601. (2014) (2)
- Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist (2016) (2)
- Comparative characterization of four purified lysine-specific transfer ribonucleic acids from chicken embryos. (1977) (2)
- Can anthocyanins improve maintenance therapy of Ph+ acute lymphoblastic leukaemia? (2013) (2)
- Safety data of MGN1601, a tumor vaccine, made of allogeneic, transfected, and irradiated tumor cells in combination with an immunomodulator for the treatment of metastatic renal cell carcinoma. (2010) (2)
- TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo. (2017) (2)
- Preclinical efficacy data of MGN1601, a tumor vaccine comprising 4-fold gene-modified and irradiated allogeneic tumor cells in combination with a DNA-based immunomodulator for the treatment of metastatic renal carcinoma. (2010) (2)
- Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma. (2012) (1)
- Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601. (2013) (1)
- 1642PThe TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo (2017) (1)
- O-0012UPDATED RESULTS OF THE RANDOMIZED PHASE 2 IMPACT TRIAL: MAINTENANCE WITH TLR-9 AGONIST MGN1703 VS PLACEBO IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC) (2013) (1)
- A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models (2018) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma. (2012) (1)
- Alexander Rich 1924–2015 (2015) (1)
- Transcription is associated with Z-DNA formation in metabolically active permeabilized mammalian cell nuclei (1991) (1)
- Assessment of parental genomic proportions in crossbred chickens by DNA fingerprints. (1997) (1)
- Transplantation of DBA/2 Mouse Corneas in BALB/c Recipients SignificantlyDelays Graft Rejection Compared with C3H Grafts and FacilitatesStudies on Gene Transfer (2008) (1)
- Approaches to Studying the Interaction between G-Proteins and Voltage- Dependent Ca2+ Channels (1993) (1)
- A strategy for the construction of double-stranded DNA microcircles with circumferences less than 50 bp. (1990) (1)
- Sequencing refractory GC rich regions in plasmid DNA. (1987) (1)
- Abstract 2622: Two new TLR9 agonists for cancer immunotherapy: Combination with checkpoint inhibitors (2017) (1)
- 47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study (2010) (1)
- New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma. (2012) (0)
- Prevention of Ph + Acute Lymphoblastic Leukemia by Nanoparticulate Delivery of a DNA Vaccine in Syngeneic Mice. (2007) (0)
- Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral , Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides 1 (2003) (0)
- Growth Factors Quantification of human cells in NOD / SCID mice by duplex real-time polymerase-chain reaction (2001) (0)
- 46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study (2010) (0)
- Closed nucleic acid molecula covalently for immune-stimulation. (2000) (0)
- A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study. (2012) (0)
- Pharmacokinetic and pharmacodynamic data of the immunotherapeutic TLR-9 agonist MGN1703 from healthy volunteers and cancer patients. (2015) (0)
- Harnessing the Therapeutic Potential of Dendritic Cells (2020) (0)
- Abstract A035: Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR-9 agonist MGN1703 – conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients (2016) (0)
- Immunological and first anti-tumor data of the TLR9 agonist dSLIM2006 (2017) (0)
- MGN1703, a Novel TLR9-Agonist - Results of a Phase 1 Clinical Trial in Patients with Metastatic Malignancies. (2009) (0)
- 740. The TLR9 Agonist EnanDIM® - Evaluation of New Enantiomeric Oligonucleotides for Cancer Immunotherapy In Vitro and In Vivo (2016) (0)
- 816. Development of Potent DNA Vaccines by Coupling of Linear MIDGE Vectors to Peptides (2004) (0)
- Antigen Presenting Cells (APC's) in Murine Corneas (2002) (0)
- Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). (2013) (0)
- Direct Determination of Chloramphenicol Acetyltransferase (CAT) Activity in Homogenates of Transfected Mammalian Cells by High Performance Liquid Chromatography (1990) (0)
- Site directed in-vitro assembly of nucleosomes. (1982) (0)
- 30PSafety, pharmacokinetics and pharmacodynamics from a clinical trial with healthy volunteers using the immunotherapeutic TLR-9 agonist MGN1703 (2015) (0)
- Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified, and irradiated tumor cells in combination with an immunomodulator in patients with metastatic renal cell carcinoma (ASET study). (2011) (0)
- Identification of G-Proteins Involved in the Inhibition of Ca2+ Currents in Neuronal and Endocrine Cells (1992) (0)
- Means for treatment of infections with Leishmania (2004) (0)
- Abstract 2565: Conformation overrides base sequence - insights from a novel class TLR-9 agonists (2014) (0)
- Vaccin contre les infections au lentivirus comme le virus de l'immunodeficience feline du chat (2000) (0)
- Method and agent for the treatment of immune responses in the eye (2000) (0)
- Transcripts in Human Myeloid Leukemias Lack of Interferon Consensus Sequence Binding Protein (ICSBP) (2013) (0)
- 6149 POSTER Preliminary Results of a Phase 2-3 Clinical Study With the Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma (IMPACT Study) (2011) (0)
- Abstract LB-233: Immune-related efficacy data of the phase 1-2 study of an with fourfold gene-modified allogeneic tumor cell based vaccine in patients with advanced renal cell carcinoma (2012) (0)
- Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study. (2011) (0)
- Combination of TLR9 agonists EnanDIM with checkpoint inhibitors for cancer immunotherapy. (2017) (0)
- Topologically fixed matrix bound nucleic acid (1997) (0)
- Synergism Between Imatinib Mesylate and a BCR-ABL-Specific DNA Vaccine against Pre-Established Ph + Acute Lymphoblastic Leukemia in Syngeneic Mice. (2009) (0)
- 19PImmunomodulation and inhibition of tumor growth by a new class of TLR9 agonists – EnanDIM (2016) (0)
- Synergism Between Chemotherapy with 6-Mercaptopurine and DNA Vaccination Against Ph+ Acute Lymphoblastic Leukemia In Syngeneic Mice (2010) (0)
- Evaluation of oligonucleotide probes for simple tandem repeats (STR) to produce informative DNA fingerprints of the chicken. (1998) (0)
- 44LBA Results of a phase I clinical trial of MGN1703, a novel TLR9-agonist, in patients with metastatic malignancies (2009) (0)
- Abstract B067: Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM (2016) (0)
- Abstract 5557: EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models (2018) (0)
- Abstract A034: Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma (2016) (0)
- Preliminary safety data of an ongoing phase I-II clinical study with the tumor vaccine MGN1601 in patients with advanced renal cell carcinoma. (2011) (0)
- Intratumoral dispersion, retention, systemic biodistribution and clearance of a small-size TNF-α expressing MIDGE vector following nonviral in vivo jet-injection gene transfer (2012) (0)
- Microprojectile for introducing substances into cells by ballistic transfer (1996) (0)
- MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy. (2015) (0)
- 56PModulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy (2017) (0)
- Inhibition of G proteins by antisense drugs (1998) (0)
- Form Follows Function: The Design of Minimalistic Immunogenically Defined Gene Expression (MIDGE®) Constructs (2007) (0)
- Method for enrichment of cells that have been modified by ballistic transfer (1994) (0)
- Antileukemic Efficacy of Anthocyanins In-Vitro and In-Vivo and In Combination with a DNA Vaccine Against Ph+ Acute Lymphoblastic Leukemia (2010) (0)
- Optimization of a BCR-ABL-Specific DNA Vaccine against Ph+ ALL Using a Nonviral Vector System and Nanoparticle Delivery (2008) (0)
- Induction of tumor-specific immune responses by the TLR9 agonist EnanDIM in murine syngeneic tumor models (2019) (0)
- IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma. (2014) (0)
- R-loop hybridization of collagen DNA: Separation in Cs2SO4 gradients (1980) (0)
- Catenate zur immunstimulation (2008) (0)
- 646. Covalently-Closed, Dumbbell-Shaped Double-Stem-Loop DNA Constructs (dSLIM) with Specific Immunomodulatory Function (2004) (0)
- No evidence for 'stress' alpha-globin genes in chicken. (1982) (0)
- 213. Treatment with MGN1601 Induces Immune Responses Against Tumor Associated Antigens in Patients with Renal Cell Carcinoma (2015) (0)
- Oligonucleotides immunomodulateurs en association avec des mesures chimiotherapeutiques (2005) (0)
- BCR-ABL Specific Sequences Are Required To Prevent Ph+ Acute Lymphoblastic Leukemia in Syngeneic Mice by DNA Vaccination. (2006) (0)
- Interferon- (cid:1) , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia (2002) (0)
- Abstracts from the 4th ImmunoTherapy of Cancer Conference (2017) (0)
- 2089 Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study (2015) (0)
- DNA-Medicine: About preventive or therapeutic gene expression and DNA-based immunomodulation (2005) (0)
- The Novel Cancer Vaccine, Consisting of Genetically Modified Allogeneic Tumor Cells and Immunomodulator MGN1601: Updated Results of a Phase 1-2 Study in Patients with Advanced Renal Cell Carcinoma (2012) (0)
- shRNA from MIDGE vectors (2007) (0)
- Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703 (2015) (0)
This paper list is powered by the following services:
Other Resources About Burghardt Wittig
What Schools Are Affiliated With Burghardt Wittig?
Burghardt Wittig is affiliated with the following schools:
